Clinical lymphoma, myeloma & leukemia · 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Decaudin Didier, Mounier Nicolas, Tilly Hervé, Ribrag Vincent, Ghesquières Hervé, Bouabdallah Krimo, Morschhauser Franck, Coiffier Bertrand, Le Gouill Steven, Bologna Serge, Delarue Richard, Huynh Anne, Bosly André, Brière Josette, Gisselbrecht Christian
Аннотация
BACKGROUND: This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas.
PATIENTS AND METHODS: From March 2005 to August 2006, 77 prospective patients were included, 69 (90%) with follicular lymphomas.
RESULTS: The last salvage chemotherapy regimen included rituximab for 74 patients and ASCT for 75 patients. Before ASCT, rates of complete response/unconfirmed response (CR/CRu) and partial response were 77% and 23%, respectively. After zevaline-BEAM (Z-BEAM), time to >1 × 10(9)/L neutrophils was 12 days (range, 9-35 days), and time to >20 × 10(9)/L platelets was 12 days (range, 3-42 days). No other significant extrahematologic toxicity was observed. Three months after ASCT, 68 patients (88%) were in CR/CRu. After a median follow-up of 28 months, 2-year event-free survival (EFS) and overall survival were 63% and 97%, respectively, but EFS for first-relapsed patients was 72%. When using patients as their own controls, 2-year EFS was superior after ASCT and compared favorably with the duration of response of last chemotherapy (62% vs. 37%, P = .007) (Point 1.10).
CONCLUSION: Z-BEAM appears safe and needs to be further evaluated in a randomized trial.
PATIENTS AND METHODS: From March 2005 to August 2006, 77 prospective patients were included, 69 (90%) with follicular lymphomas.
RESULTS: The last salvage chemotherapy regimen included rituximab for 74 patients and ASCT for 75 patients. Before ASCT, rates of complete response/unconfirmed response (CR/CRu) and partial response were 77% and 23%, respectively. After zevaline-BEAM (Z-BEAM), time to >1 × 10(9)/L neutrophils was 12 days (range, 9-35 days), and time to >20 × 10(9)/L platelets was 12 days (range, 3-42 days). No other significant extrahematologic toxicity was observed. Three months after ASCT, 68 patients (88%) were in CR/CRu. After a median follow-up of 28 months, 2-year event-free survival (EFS) and overall survival were 63% and 97%, respectively, but EFS for first-relapsed patients was 72%. When using patients as their own controls, 2-year EFS was superior after ASCT and compared favorably with the duration of response of last chemotherapy (62% vs. 37%, P = .007) (Point 1.10).
CONCLUSION: Z-BEAM appears safe and needs to be further evaluated in a randomized trial.
Предметные рубрики MeSH
AdolescentAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineHematopoietic Stem Cell TransplantationHumansLymphoma, B-CellMelphalanMiddle AgedNeoplasm StagingPodophyllotoxinRituximabSurvival AnalysisTransplantation, AutologousTreatment OutcomeYoung Adult